FDA warns of drug interaction with clopidogrel and omeprazole
The FDA has notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel bisulfate (Plavix, from Bristol-Myers Squibb and sanofi-aventis), a platelet aggregation inhibitor, and omeprazole (Prilosec, from AstraZeneca; and Prilosec OTC, from Procter & Gamble), a proton pump inhibitor (PPI).
The e-mail address(es) that you supply to use this service will only be used to send the requested article.